

Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.

NCT07390851

Status	RECRUITING
Phase	Not Applicable
Sponsor	Cairo University
Enrollment	28 participants

Key Eligibility Criteria

Inclusion (8)

- Age between 18 and 70 years.
- Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).
- Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).
- Pain duration e 3 months.
- Pain intensity e 4 on the Visual Analog Scale (VAS).

... and 3 more (see full listing online)

Exclusion (8)

- Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.
- Current use of anticoagulants or history of bleeding disorders.
- Systemic or local infection at or near the injection site.
- History of fibromyalgia, central pain syndromes, or cancer-related pain.
- Major psychiatric illnesses (e.g., schizophrenia, severe depression).

... and 3 more (see full listing online)

Locations (1 total)

Faculty of oral and dental medicine, cairo university, Giza, Giza Governorate, Egypt